Research programme: inhaled antibody-based therapeutics - Aridis Pharmaceuticals/Lumen Bioscience
Latest Information Update: 08 Mar 2022
Price :
$50 *
At a glance
- Originator Aridis Pharmaceuticals; Lumen Bioscience
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research COVID 2019 infections; Influenza virus infections